APA resolution emphasizes
behavioral and
biomedical approaches
Even a 100 percent effective pill or vaccine wouldn’t necessarily stop the HIV/AIDS epidemic, says Perry N. Halkitis, PhD, chair of APA’s Committee on Psychology
and AIDS (COPA) and professor of applied psychology, public
health and medicine at New York University’s Steinhardt
School.
That’s because biomedical interventions for preventing
or treating HIV infection depend on human behavior. And
it’s why COPA developed a resolution promoting the need to
combine behavioral and biomedical approaches to optimize
HIV prevention. APA’s Council of Representatives approved the
resolution in February.
While applauding the success of new biomedical
innovations, the resolution emphasizes that stopping the
epidemic will require approaches that address both medical and
psychosocial issues.
“Anytime you involve human beings — multifaceted,
multidimensional, very complex organisms — a simple pill is
not going to solve the problem,” says Halkitis. “The biomedical
approach gives us another weapon, but it’s a weapon that will
only be maximally effective if combined with what we have
learned in the last 30 years about human behavior around the
transmission of HIV.”
Halkitis points to the drug Truvada, which has been
used to treat HIV, as an example. In May, a Food and Drug
Administration panel recommended that FDA approve it as a
drug to prevent HIV.
“I’m thrilled,” says Halkitis. “But I’m also worried about
making sure we educate those who are taking the medication to
use it properly.”
Research shows that patients have trouble adhering to the
drug’s every-day regimen. Plus, it doesn’t exempt people from
practicing safe sex, since no pill works all the time.
Failing to adhere to the prescribed regimen can have major
consequences for the person and for society as a whole, Halkitis
adds.
“Missing or skipping doses gives the virus an opportunity
to mutate,” he says. “That’s a problem not only for the person
taking the pills but for the individuals they may be having
JULY/AUGUST 2012 • MONITOR ON PSYCHOLOGY
unsafe sex with, since they may be passing on a resistant version
of the virus.”
APA’s resolution calls for more research on behavioral
factors such as people’s willingness to start and stick with
treatment, medication adherence and decision-making, and
the development of new prevention approaches that combine
biomedical and behavioral advances. The resolution also
recommends increased funding for prevention research that
incorporates mental health, substance abuse, behavior change
and adherence strategies, plus policies that promote training,
practice and research across disciplines.
To get the word out, Halkitis and Leo Rennie, senior
legislative and federal affairs officer in APA’s Public Interest
Directorate, headed to Capitol Hill and beyond.
They met with Grant Colfax, MD, the new director of the
White House Office on National AIDS Policy, plus a staffer
for the Senate appropriations subcommittee responsible for
research funding. They also visited Ronald O. Valdiserri, MD,
deputy assistant secretary for health and infectious diseases
at the U.S. Department of Health and Human Services, who
used APA’s resolution as the basis of his talk at the “Advancing
the National HIV/AIDS Strategy in Metropolitan Washington”
conference the following day.
The response at all three meetings was excellent, says
Halkitis.
—REBECCA A. CLAY
Read APA’s resolution at www.apa.org/about/policy/
biomedical-hiv.pdf.
The 2012 International
AIDS conference will
be held July 22–27 in
Washington, D.C. For more
information on the event,
go to www.aids2012.org.
41